Last reviewed · How we verify

Lu AA21004 — Competitive Intelligence Brief

Lu AA21004 (Lu AA21004) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multimodal antidepressant; serotonin reuptake inhibitor with 5-HT1A agonist and 5-HT7 antagonist activity. Area: Psychiatry/Neurology.

phase 3 Multimodal antidepressant; serotonin reuptake inhibitor with 5-HT1A agonist and 5-HT7 antagonist activity Serotonin transporter (SERT), 5-HT1A receptor, 5-HT7 receptor Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Lu AA21004 (Lu AA21004) — H. Lundbeck A/S. Lu AA21004 is a multimodal antidepressant that acts as a serotonin reuptake inhibitor, serotonin 5-HT1A receptor agonist, and serotonin 5-HT7 receptor antagonist.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lu AA21004 TARGET Lu AA21004 H. Lundbeck A/S phase 3 Multimodal antidepressant; serotonin reuptake inhibitor with 5-HT1A agonist and 5-HT7 antagonist activity Serotonin transporter (SERT), 5-HT1A receptor, 5-HT7 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multimodal antidepressant; serotonin reuptake inhibitor with 5-HT1A agonist and 5-HT7 antagonist activity class)

  1. H. Lundbeck A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lu AA21004 — Competitive Intelligence Brief. https://druglandscape.com/ci/lu-aa21004. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: